Lexeo Therapeutics (LXEO) Consolidated Net Income (2022 - 2026)

Lexeo Therapeutics' Consolidated Net Income history runs 5 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 38.16% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$87.5 million (up 19.95% YoY), while the FY2025 annual figure was -$103.2 million, down 4.97% from the prior year.
• Consolidated Net Income came in at -$20.2 million for Q1 2026 at Lexeo Therapeutics, up from -$20.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$13.4 million in Q2 2023 to a low of -$32.7 million in Q1 2025.
• A 5-year average of -$21.1 million and a median of -$20.3 million in 2025 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income plunged 82.73% in 2024 and surged 38.16% in 2026, its largest moves.
• Lexeo Therapeutics' Consolidated Net Income stood at -$14.6 million in 2022, then increased by 2.68% to -$14.2 million in 2023, then plunged by 82.73% to -$25.9 million in 2024, then rose by 19.29% to -$20.9 million in 2025, then increased by 3.47% to -$20.2 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$20.2 million, -$20.9 million, and -$20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison